Breast Cancer Research and Treatment

, Volume 135, Issue 3, pp 849–855 | Cite as

Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer

  • Babette Siebold Saltzman
  • Kathleen E. Malone
  • Jean A. McDougall
  • Janet R. Daling
  • Christopher I. Li


Breast cancer survivors have a 60 % higher risk of developing a second primary asynchronous contralateral breast cancer (CBC) compared to women’s risk of developing a first primary breast cancer (FBC). However, little is known about how expression of tumor markers in first breast cancers influences CBC risk. We conducted a population-based nested case–control study among women 20–74 years of age diagnosed with a first breast cancer between 1996 and 2008 in western Washington State to evaluate the association between their tumor’s estrogen receptor (ER), progesterone receptor (PR) and HER2-neu (HER2) expression, and risk of CBC. The study included 482 cases diagnosed with both a FBC and a CBC and 1,506 control women diagnosed only once with breast cancer identified through our local Surveillance, Epidemiology and End Results (SEER) cancer registry. Compared to the women whose FBC was ER+/PR+, those with ER−/PR− first tumors had a 1.6-fold (95 % confidence interval (CI): 1.2–2.3) increased risk of developing a CBC. When evaluated by joint ER/PR/HER2 status, compared to women with ER+/HER2− first cancers, those with HER2-overexpressing (ER−/HER2+) and triple-negative disease (ER−/PR−/HER2−) had 2.0-fold (95 % CI: 1.1–3.8) and 1.4-fold (95 % CI: 0.9–2.3) elevated risks of developing CBC, respectively. Beyond the known higher risks of mortality among patients diagnosed with more aggressive BC subtypes, here, we observe that they may also have increased risks of developing CBC.


Breast cancer Contralateral breast cancer Epidemiology 



This work was supported by the National Cancer Institute, grant number K01-CA101970.

Conflict of interest



  1. 1.
    Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8(10):855–861PubMedGoogle Scholar
  2. 2.
    Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD (2003) The descriptive epidemiology of second primary breast cancer. Epidemiology 14(5):552–558. doi: 10.1097/01.ede.0000072105.39021.6d PubMedCrossRefGoogle Scholar
  3. 3.
    Horn PL, Thompson WD (1988) Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol 128(2):309–323PubMedGoogle Scholar
  4. 4.
    Bernstein JL, Thompson WD, Risch N, Holford TR (1992) The genetic epidemiology of second primary breast cancer. Am J Epidemiol 136(8):937–948PubMedGoogle Scholar
  5. 5.
    Horn PL, Thompson WD, Schwartz SM (1987) Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut Tumor Registry. J Chronic Dis 40(11):1003–1011PubMedCrossRefGoogle Scholar
  6. 6.
    Li CI, Malone KE, Porter PL, Daling JR (2003) Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 89(3):513–518. doi: 10.1038/sj.bjc.6601042 PubMedCrossRefGoogle Scholar
  7. 7.
    Hankey BF, Ries LA, Edwards BK (1999) The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 8(12):1117–1121PubMedGoogle Scholar
  8. 8.
    Hammock L, Lewis M, Phillips C, Cohen C (2003) Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 34(10):1043–1047PubMedCrossRefGoogle Scholar
  9. 9.
    Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59(7):729–735. doi: 10.1136/jcp.2005.033043 PubMedCrossRefGoogle Scholar
  10. 10.
    Bessonova L, Taylor TH, Mehta RS, Zell JA, Anton-Culver H (2011) Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol Biomarkers Prev 20(2):389–396. doi: 10.1158/1055-9965.EPI-10-1016 PubMedCrossRefGoogle Scholar
  11. 11.
    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi: 10.1038/35021093 PubMedCrossRefGoogle Scholar
  12. 12.
    Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101(15):1058–1065. doi: 10.1093/jnci/djp181 PubMedCrossRefGoogle Scholar
  13. 13.
    Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, Castiglione M, Vinh-Hung V, Vlastos G, Rapiti E (2011) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127(1):233–241. doi: 10.1007/s10549-010-1137-z PubMedCrossRefGoogle Scholar
  14. 14.
    Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N (2004) Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 96(7):516–523PubMedCrossRefGoogle Scholar
  15. 15.
    Tun NMV, GM Villani, Ong K (2011) Risk of having BRCA mutations in women with triple-negative breast cancer: a systematic review and meta-analysis. In: American Society of Clinical Oncology; 2011 Breast Cancer SymposiumGoogle Scholar
  16. 16.
    Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD Jr, Anton-Culver H, Bernstein JL (2010) Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 28(14):2404–2410. doi: 10.1200/JCO.2009.24.2495 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Babette Siebold Saltzman
    • 1
    • 2
  • Kathleen E. Malone
    • 1
    • 3
  • Jean A. McDougall
    • 1
    • 3
  • Janet R. Daling
    • 1
  • Christopher I. Li
    • 1
    • 3
  1. 1.Division of Public Health SciencesFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Seattle Children’s HospitalSeattleUSA
  3. 3.Department of EpidemiologyUniversity of WashingtonSeattleUSA

Personalised recommendations